These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19487489)

  • 1. Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physician-patient communication.
    Costantini A; Picardi A; Zilli M; Cairoli F; Torta R; Marchetti P; Baile W; Iacobelli S
    Ann Oncol; 2009 Oct; 20(10):1647-52. PubMed ID: 19487489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
    Imai H; Kuroi K; Ohsumi S; Ono M; Shimozuma K
    Breast Cancer; 2007; 14(1):81-7. PubMed ID: 17245000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 62-year-old woman with a new diagnosis of breast cancer.
    Come SE
    JAMA; 2006 Mar; 295(12):1434-42. PubMed ID: 16551716
    [No Abstract]   [Full Text] [Related]  

  • 5. The economic consequences of breast cancer adjuvant hormonal treatments.
    Pezzin LE; O'Niel MB; Nattinger AB
    J Gen Intern Med; 2009 Nov; 24 Suppl 2(Suppl 2):S446-50. PubMed ID: 19838848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.
    Barni S; Collovà E; Frassoldati A; Amoroso D
    Future Oncol; 2015; 11(8):1181-9. PubMed ID: 25832875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
    Pritchard KI
    J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
    [No Abstract]   [Full Text] [Related]  

  • 10. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
    van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
    Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
    Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A; Verma S
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is adjuvant tamoxifen used optimally in the treatment of breast cancer? Results of an Italian survey.
    Valentini M; Mari E; Belfiglio M; Nicolucci A
    Ann Oncol; 1999 Jul; 10(7):789-93. PubMed ID: 10470425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.